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Edited by Berend WieringaAbstract Friedreich’s ataxia (FRDA) is an autosomal recessive
trinucleotide repeat disease with no eﬀective therapy. Expanded
GAA repeats in the ﬁrst intron of the FRDA gene are thought to
form unusual non-B DNA conformations that decrease tran-
scription and subsequently reduce levels of the encoded protein,
frataxin. Frataxin plays a crucial role in iron metabolism and
detoxiﬁcation. To discover small molecules that increase tran-
scription through the GAA repeat region in FRDA, we have
made stable cell lines containing a portion of expanded intron
1 fused to a GFP reporter. Small molecules identiﬁed using the
competition dialysis method were found to increase FRDA-in-
tron 1-reporter gene expression. One of these compounds, pent-
amidine, increases frataxin levels in patient cells. Thus our
approach can be used to detect small molecules of potential ther-
apeutic value in FRDA.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Friedreich’s ataxia (FRDA) is the most common inherited
ataxia, aﬀecting approximately 1 in 50000 people [1]. Most pa-
tients with FRDA have a pathogenic expansion of a trinucleo-
tide repeat (GAA) within the ﬁrst intron of the X25 gene (also
known as FRDA or FXN). The expanded GAA repeats are
thought to form unusual non-B DNA conformations that de-
crease transcription and subsequently reduce levels of the en-
coded protein, frataxin [2,3]. Frataxin is a highly conserved
mitochondrial protein that plays a crucial role in providing
iron for heme synthesis and the formation of Fe–S clusters
[4]. Other work has shown that frataxin is important for iron
detoxiﬁcation [5]. Currently there are no eﬀective treatments
for FRDA patients, whose cardinal clinical features include
progressive gait and limb ataxia, lower limb muscle weakness
and dysarthria [4,6,7]. Other symptoms include hypertrophic
cardiomyopathy, diabetes and vision problems [4,6,7]. Given*Corresponding author. Fax: +1 601 984 1501.
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doi:10.1016/j.febslet.2006.09.006the putative role of frataxin, idebenone antioxidative therapy
is being evaluated in clinical trials [8,9]. This compound has
been shown to have cardioprotective eﬀects in a mouse model
of FRDA [10], although conﬂicting data regarding the role of
oxidative damage in this disease exist [11]. Other approaches to
treat FRDA are centered upon increasing the expression of
frataxin. For example, a recent study has found that recombi-
nant human erythropoietin increases frataxin levels, by an un-
known mechanism, in cultured cells from FRDA patients [12].
Another strategy to increase frataxin involves using reagents
that can attenuate the recalcitrant conformations (triplex or
sticky DNA) expanded GAA repeats are thought to take,
thereby increasing transcription and elevating frataxin levels.
Recently, Gottesfeld and colleagues have shown in elegant
work that polyamides that bind speciﬁcally to GAA repeats
can increase frataxin mRNA and protein levels in an FRDA
lymphoid cell line [13].
Competition dialysis is a very powerful technique that can be
used to discover ligands that bind nucleic acids with structural-
or sequence-selectivity [14]. As such, this method can conceiv-
ably be used to identify small molecules that bind selectively to
the duplex form of the GAA repeat sequence over the triplex
form. Such molecules will shift the equilibrium to reverse tri-
plex formation, thereby inhibiting the unfavorable biological
eﬀects of triplex formation. Information gathered from the
ﬁrst-generation competition dialysis assay, in which binding
data was gathered for the interaction of 126 compounds with
13 diﬀerent nucleic acid structures and sequences [14], was used
to identify small molecules that have the potential to increase
transcription through the GAA repeats found in FRDA. We
describe in this report the initial characterization of a subset
of these compounds.2. Materials and methods
2.1. Stable cell line construction
Normal (GAA15) and expanded (GAA148) genomic DNA was used
as a template in a PCR reaction using previously described primers and
conditions to amplify a fragment of the X25/FRDA/FXN intron 1 (note
28 in [15]). These primers generate a 1.4 kb normal fragment that was
subsequently digested with BamHI and XmaI and cloned into pEGFP-
N3 (Clontech, Palo Alto, CA) cut with BglII and XmaI. In so doing,
the partial intron 1 sequence containing the GAA repeats is positioned
upstream of the GFP coding sequence. Thus alterations in the ability
to transcribe through this repeat will impact GFP expression. HeLablished by Elsevier B.V. All rights reserved.
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mids using G418 selection per the manufacturer’s instructions (Clon-
tech). Three independently isolated cell lines were obtained for each
construct.
2.2. Cell culture and small molecule treatment
GAA15-GFP or GAA148-GFP cell lines were cultured (37 C, 5%
CO2) in DMEM medium (Invitrogen; Carlsbad, CA) supplemented
with 10% fetal calf serum and penicillin/streptomycin. To monitor
the eﬀects of small molecules on the expression of GFP, GAA148-
GFP cells were seeded into six T25 ﬂasks such that the ﬂasks were
30% conﬂuent on the day of the experiment. Speciﬁc compounds were
added to three of the ﬂasks at the indicated ﬁnal concentrations, the
remaining three ﬂasks received vehicle only. All small molecules were
purchased from Sigma (St. Louis, MO). After 48 h of incubation, cells
were harvested and vortexed in 20 ll of high salt lysis buﬀer (50 mM
Tris, pH 7.5, 0.5 M NaCl, 1% NP-40, 1% sodium deoxycholate,
0.1% SDS, 2 mM EDTA), followed by a brief spin in a microcentrifuge
and the addition of 20 ll of low salt lysis buﬀer (same as high salt, ex-
cept 150 mM NaCl). The cell suspension was vortexed brieﬂy and cen-
trifuged for 5 min at full speed in a microcentrifuge at 4 C. Protein
concentration was determined using the BioRad protein assay (BioRad
Laboratories, Hercules, CA). For immunoﬂuoresence experiments,
cells were grown in chambered slides, treated with the indicated com-
pound and processed as described previously [16] after 48 h of incuba-
tion.
2.3. Western blotting and immunoﬂuoresence analysis
Equal amounts of protein were added to 5· SDS loading buﬀer,
boiled and subject to SDS–PAGE (12% gel) and Western blotting as
previously described [17]. Each gel contained three independently iso-
lated treated and untreated samples. The blot was probed with mono-
clonal anti-GFP antibodies (Roche, Indianapolis, IN), followed by the
detection of SMN using a monoclonal antibody from BD Biosciences
(Palo Alto, CA). Chemiluminescent signals were captured by X-ray
ﬁlm and quantiﬁed using NIH Image 1.63 image analysis software.
The GFP signals of some of the untreated samples in Fig. 2 are faintly
detectable due to short exposure times. GAA15-GFP or GAA148-GFP
cell images were captured using a Nikon Eclipse E600 epiﬂuorescent
microscope with a Coolsnap fx digital camera (Roper Scientiﬁc, Tucs-
con, AZ) controlled by MetaView (Series 5) image capturing and pro-
cessing software (Universal Imaging Corporation, Downingtown, PA).
Pixel intensities were obtained using this software. Adobe Photoshop
7.0 (San Jose, CA) was used for the ﬁnal processing of the images
and labeling.
2.4. FRDA lymphocyte isolation and pentamidine treatment
Four patients with FRDA (GAA repeats in the range from 107 to
1305) were included in this study after the University of Mississippi
Medical Center Institutional Review Board approved the protocol.
Lymphocytes from fresh blood samples were isolated using Ficoll-
Paque density gradients and cultured for 48 h in RPMI supplemented
with 10% fetal calf serum, 2 mM L-glutamine and antibiotics. Where
indicated, pentamidine was added to a ﬁnal concentration of 30 lM.
After incubation, lymphocytes were harvested, lysed and subjected to
SDS–PAGE and Western transfer, followed by the detection of fra-
taxin and SMN. A polyclonal antibody to frataxin (H-155, Santa Cruz
Biotechnology, Santa Cruz, CA) was used for these experiments. All
samples, except one, were subject to technical duplicates (in which
the lysates were subjected to SDS–PAGE and frataxin and SMN detec-
tion twice). Limited material precluded a technical duplicate for the
sample with 165 GAA repeats on one allele and 107 repeats on the
other allele.
2.5. Statistical analysis
The ratio of GFP to SMN or frataxin to SMN is used to determine if
a small molecule signiﬁcantly increases GFP or frataxin expression
through GAA repeats. For example, the GFP (or frataxin) signal for
a certain drug at a certain concentration was quantiﬁed and divided
by the SMN signal at this same condition. This ratio was compared
to the ratio found in cells that did not receive treatment. Drugs which
increase GFP (or frataxin) expression relative to SMN will yield num-
bers greater than 1. Signiﬁcant diﬀerences were determined using
Student’s t-test (a P-value of less than 0.05 is considered signiﬁcant).To calculate diﬀerences in the ﬂuorescence signal between cell lines
and treatments, pixel intensities were determined followed by the appli-
cation of Student’s t-test (P-value of less than 0.05 is considered signi-
ﬁcant).3. Results and discussion
Previous studies have shown that expanded GAA tracts re-
duce the expression of a reporter gene when transiently trans-
fected into COS-7 cells [18]. To facilitate the identiﬁcation of
small molecules that increase transcription through expanded
GAA repeats in living cells, we made stable cell lines in which
a fragment of the X25 intron 1 that contains the GAA repeats
was transcriptionally fused upstream of a GFP reporter
(Fig. 1). Two lines were made, one with a normal number of
repeats (15) and another with an expanded tract (148). To
demonstrate that these cell lines could be used for screening
small molecules with therapeutic value to FRDA patients,
we monitored the GFP signal for both cell lines by ﬂuorescence
microscopy and Western blotting. As can be observed in
Fig. 1B, there is a statistically signiﬁcant decrease in the
GFP signal of cells with 148 repeats compared to the signal
in cells with 15 repeats (P = 1.2113, compare panel a to panel
c). Importantly, when cells are grown in the presence of 4 0,6-
diamidino-2-phenylindole (DAPI), a known binder of duplex
DNA, the level of GFP expression increases in the GAA148-
GFP cell line (P = 0.00018) but remains essentially unchanged
in the GAA15-GFP line (P = 0.6, compare d–c and b–a). The
decrease in GFP expression as a consequence of expanded
GAA repeats was also veriﬁed by Western blotting (Fig. 1C).
Consistent with the microscopic observations, the level of
GFP in GAA148-GFP cells, relative to SMN, is increased when
cells are incubated with DAPI (Fig. 1C). SMN, the survival of
motor neurons protein, serves an essential housekeeping func-
tion in the assembly of the spliceosomal machinery [19] and
can therefore be used as a general transcription monitor and
loading control. In contrast to the GAA148-GFP results, DAPI
treatment does not aﬀect the GFP/SMN ratio in GAA15-GFP
cells. From these results we conclude that the GAA148-GFP
cell line represents an appropriate model to test the eﬀects of
small molecules on the transcription through GAA repeats.
Small molecules with the potential to bind selectively to the
duplex form of the GAA repeat sequence were identiﬁed by
analysis of data obtained from the ﬁrst generation competi-
tion dialysis screening assay in which the interactions of 126
compounds with 13 nucleic acid structures were studied
[20,14]. Classic groove binding agents were identiﬁed by the
competition dialysis to prefer duplex over triplex forms, and
would in fact displace the third strand to form a drug-duplex
DNA complex [21]. The compounds DAPI, Hoechst 33258,
distamycin, diminazene, netropsin and chromomycin were
selected for the reporter assay by this approach. Pentamidine,
while not tested by competition dialysis, was also selected
based on its known properties as a groove-binding agent [22].
We next wanted to test if the compounds identiﬁed by the
competition dialysis method can increase expression of the
GFP reporter. Ideally, small molecules can be identiﬁed that
upregulate GFP expression but do not aﬀect the transcription
of other genes or alter cell viability. The compounds were ini-
tially tested on the GAA148-GFP cell line using 5 lM and
50 lM ﬁnal concentrations. At 5 lM, chromomycin had severe
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Fig. 1. The number of GAA repeats alters reporter gene expression. (A) Schematic of the stable cell lines used in this study. (B) GAA15-GFP (line A)
or GAA148-GFP (line A) cells were untreated or treated with 10 lM DAPI for 48 h and images were obtained using ﬂuorescence microscopy (1 s
exposure). The pixel intensity for each cell was determined and the average pixel intensity for each ﬁeld is shown at the bottom left of each panel.
Scale bar = 20 lm. (C) Equal amounts of protein from untreated or DAPI treated GAA15-GFP (line A) or GAA148-GFP (line A) cells were run on a
SDS–PAGE gel, followed by Western transfer and detection of the GFP reporter by anti-GFP antibodies. The blot was reprobed with anti-SMN to
verify equal protein loading. In untreated cells, the expression of GFP is reduced relative to SMN in cells with 148 GAA repeats compared to 15
GAA repeats. DAPI treatment increases the ratio of GFP to SMN in GAA148-GFP cells.
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toxic at 50 lM ﬁnal concentration, so additional assays were
conducted on this compound using 10, 20 and 30 lM. For
each assay, GAA148-GFP cells were treated with small mole-
cules at the indicated concentration for 48 h, followed by cell
lysis, total protein isolation and detection of GFP by anti-
GFP antibodies. The same blot was reprobed with antibodies
to SMN to monitor the eﬀects the small molecule may have on
the transcription of other genes. As shown in Fig. 2, all of the
compounds except netropsin elicit a statistically signiﬁcant
increase in the expression of the GFP reporter at a 5 lM
concentration. For example, treatment of the GAA148-GFPcell line with 5 lM Hoechst 33258 increases the ratio of GFP
to SMN by 24.2-fold compared to the GFP/SMN ratio in
untreated cells (Fig. 2, panel D (top), panel G). 5 lM DAPI
and pentamidine treatment yielded smaller, yet statistically
signiﬁcant increases in the expression of GFP (Fig. 2, panel
B (top), panel E (top), panel G). Speciﬁcally, there was a
2.6-fold increase (P = .015) in GFP expression in DAPI treated
cells, and a 1.65-fold increase (P = .0086) in pentamidine trea-
ted cells. Higher compound concentrations produced corre-
spondingly higher levels of GFP reporter induction relative
to SMN. However, we observed a decrease in the expression
of SMN at higher small molecule concentrations, indicating
A B
DC
E F
G
Fig. 2. Some small molecules identiﬁed by competition dialysis increase reporter gene expression. GAA148-GFP (line A) cells were untreated () or
treated (+) with the indicated small molecule for 48 h, followed by detection of GFP and SMN by Western blotting. The results using 5 lM and
50 lM ﬁnal concentrations of the small molecules are shown, with the exception of pentamidine (panel E) in which 5 lM, 10 lM, 20 lM and 30 lM
results are displayed. The histogram (panel G) shows the fold diﬀerence of the ratio of GFP to SMN in 5 lM treated GAA148-GFP (line A) cells
compared to untreated cells. No change in the ratio will yield 1 (denoted by dashed horizontal line). At this concentration, all compounds except
netropsin produce signiﬁcant increases in the expression of GFP relative to SMN. The P-values for DAPI and pentamidine are shown (P < 0.05 is
considered signiﬁcant).
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doses.
To generalize these results, we tested additional cell lines
containing 15 or 148 GAA repeats with 5 lM of the small
molecules. We do not observe statistically signiﬁcant changesin the ratio of GFP to SMN in cell lines with 15 GAA repeats
upon treatment with the various small molecules (Fig. 3,
panels A–C). In contrast, additional cell lines with 148 GAA
repeats respond similarly to the diﬀerent small molecules as
found for the line used previously in Fig. 2 (Fig. 3. panels D
AD
B
C
G
F
E
Fig. 3. Small molecules increase the expression of the GFP reporter in additional cell lines with 148 repeats but do not alter GFP expression in lines
with 15 GAA repeats. (A–C) Three independently derived GAA15-GFP cell lines (lines A, B and C) were untreated or treated with 5 lM of the
indicated small molecule, followed by total protein isolation and Western blotting for GFP and SMN. No signiﬁcant increase in the expression of
GFP was detected upon small molecule treatment for any of the cell lines. (D and E) Two additional GAA148-GFP cell lines (lines B and C) were
untreated or treated with 5 lM of the indicated small molecule and processed as described above. At this concentration, all compounds produce
statistically signiﬁcant increases in the expression of GFP relative to SMN (F and G), with the exception of netropsin in GAA148-GFP (line C). NS –
not signiﬁcant.
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in the expression of GFP relative to SMN in all three GAA148-
GFP cell lines (Figs. 2, panel G and 3 panels F and G). It is not
known why Hoechst 33258 produces such a dramatic increase
in reporter expression. Studies on Hoechst 33258 binding
in vitro have shown that it shows a strong sequence preference
for runs of 4–6 A–T bp, where it binds in the minor groove. G–
C bp are thought to disfavor binding because of an amino
group that protrudes into the minor groove, hindering the ste-
reochemical ﬁt [23,24]. Other work has shown that Hoechst
33258 can bind RNA [25] and exhibit antimicrobial activity[26]. There are no explicit data for the preferential binding of
Hoechst 33258 to GAA repeats, yet our cell reporter studies
clearly show that this compound is a very eﬀective inducer of
GFP expression. One possibility is that Hoechst 33258 pro-
motes GAA duplex formation and induces an open chromatin
complex that facilitates transcription and translation.
Netropsin was the only tested compound that did not signif-
icantly induce reporter expression in all three cell lines (Figs. 2,
panel G and 3 panels F and G). Interestingly, GAA148-GFP
(line B) showed only a modest increase in GFP expression
upon diminazene treatment compared to that found in
5404 LaKechia Grant et al. / FEBS Letters 580 (2006) 5399–5405GAA148-GFP (line A), yet Hoechst 33258 yielded an almost
identical fold-induction in both cell lines. The eﬀects of some
small molecules in GAA148-GFP (line C) seem muted com-
pared to that found in the other two lines. Hoechst 33258,
for example, increases GFP reporter expression 7.1-fold in
GAA148-GFP (line C) but 24.2-fold in GAA148-GFP (line A)
and 29-fold in GAA148-GFP (line B). It is possible that the ob-
served diﬀerences in GFP induction are a consequence of dif-
ferent chromatin contexts into which the reporter construct
was integrated in each cell line. Nevertheless, the fact that all
three GAA148-GFP cell lines showed signiﬁcant increases in
GFP reporter expression upon treatment with the same ﬁve
compounds demonstrates their utility as a resource to identify
molecules that promote transcription through GAA repeats.
To obtain information about the longevity of GFP upregu-
lation in response to small molecules, we conducted experi-
ments in which cells were treated with compounds followed
by incubation in medium without the compound. In brief,
GAA148-GFP cells were treated for 48 h with 10 lM pentami-
dine or distamycin, followed by PBS wash and 48 h incubation
in medium without the small molecule. As shown in Fig. 4, the
amount of GFP signal relative to SMN is greatly increased in
cells subject to PBS wash and subsequent 48 h incubation com-
pared to cells treated for 48 h only (compare GFP signal in
lanes 2 and 3 to that found in lanes 5 and 7). These ﬁndings
demonstrate that small molecules identiﬁed by competition
dialysis bind with high speciﬁcity and continue to exert beneﬁ-Fig. 4. Small molecules can increase reporter gene expression after
exposure and incubation in medium lacking the small molecule.
GAA148-GFP (line A) cells were untreated (lane 1) or treated (10 lM)
for 48 h with the indicated small molecule (lanes 2 and 3), followed by
PBS wash and incubation a further 48 h. Extract from untreated cells
subject to the wash and additional incubation was loaded in lanes 4, 6
and 8. Lanes 5 and 7 were initially incubated with pentamidine and
distamycin, respectively. GFP and SMN were detected by immuno-
blotting.
Fig. 5. Pentamidine increases the expression of frataxin in patient tissue. W
numbers were isolated and cultured in the presence (+) or absence () of 30
detection of frataxin (top panel) and SMN (bottom panel) by immunoblo
determined. For each patient sample, the average fold increase of frataxin
duplicates were conducted for all samples except where indicated by an asteris
allele).cial eﬀects on transcription through GAA repeats even after
excess compound has been removed.
In order to examine if small molecules identiﬁed by compe-
tition dialysis and screened by the cell reporter system also in-
crease endogenous frataxin levels in patient cells, we cultured
patient lymphocytes with 30 lM pentamidine. Although this
compound does not increase GFP reporter expression to the
same extent as other tested molecules such as DAPI or Hoe-
chst 33258 (Figs. 2 and 3), pentamidine was chosen for this
assay because it is approved for the treatment of infections
in patients with HIV and thus can be easily tried in FRDA pa-
tients. Four diﬀerent patients with diﬀering GAA repeat
lengths were tested. In all cases, we ﬁnd that frataxin levels
are increased relative to SMN upon pentamidine treatment
(Fig. 5). As expected, samples with the highest repeat numbers
have the least amount of induction. A previous report has
shown that healthy FRDA carriers have around 40% of the
normal frataxin mRNA level [27]. Consequently, a modest in-
crease in frataxin levels, such as that induced by pentamidine,
may be suﬃcient to moderate the symptoms of FRDA.
Here we report the generation of stable cell lines that can be
used to screen compounds for their ability to promote tran-
scription through expanded GAA repeats found in Friedr-
eich’s ataxia. We note that the GFP signal from all three
lines with 148 GAA repeats is signiﬁcantly decreased com-
pared to the signal from the three lines with 15 GAA repeats
(Figs. 1 and 3). This ﬁnding strongly supports, but does not
unequivocally prove, that the reduced expression of GFP in
the 148 repeat cell lines is the result of the expanded GAA re-
peats and not a consequence of other factors such as a trans-
gene integration site that depresses GFP expression. We also
note that our use of the housekeeping protein SMN as a load-
ing control is valid given that its expression does not signiﬁ-
cantly change relative to GFP upon diﬀerent treatments in
the cell lines with 15 GAA repeats (Fig. 3). Although not con-
ducted in this study, these cell lines can be adapted for high
throughout drug screening using a plate reader format. Small
molecules identiﬁed using the competition dialysis method
were found to signiﬁcantly increase cellular FRDA-reporter
gene expression. These studies therefore demonstrate the feasi-
bility and validity of this approach to uncover small molecules
of potential therapeutic value in FRDA. Notably, we show in
this report that pentamidine, which is approved for the treat-
ment of infections in patients with HIV, can increase frataxin
levels in cultured patient lymphocytes. We are currently testinghite blood cells from FRDA patients with the indicated GAA repeat
lM pentamidine for 48 h. Total protein was isolated followed by the
tting. Signals were quantiﬁed and the ratio of frataxin to SMN was
relative to SMN upon pentamidine treatment is shown. Technical
k (this patient has 165 repeats on one allele and 107 repeats on the other
LaKechia Grant et al. / FEBS Letters 580 (2006) 5399–5405 5405if other small molecules identiﬁed in this report can also in-
crease frataxin levels in patient cells.
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